Generation Lab announced the general availability of SystemAge 2.1, the latest version of its Biological Noise measurement platform.
The company said SystemAge 2.1 is the first biological age test to offer dedicated male and female versions.
The new release adds sex-specific aging analysis, skin and mitochondrial function tracking, and a longitudinal trend view that shows how patients age over time.
Generation Lab said SystemAge 2.1 measures more than 460 biomarkers across 21 organ systems from a single needle-free blood draw.
The company said the platform has 99% accuracy validated across 1,605 test cases.
SystemAge 2.1 is built on more than two decades of aging research from Generation Lab co-founder Prof. Irina Conboy, PhD, previously of UC Berkeley.
Generation Lab said its published research has shown that men and women age along different timelines, with different biological drivers and different intervention points.
The company said earlier biological age tests have generally relied on one model for both men and women, which can miss sex-specific differences in aging patterns.
The new version includes male and female-specific testing across the same 21 organ systems.
SystemAge 2.1 also adds new organ coverage for Skin and Connective Tissue, the Reproductive System, and Mitochondrial Function.
The platform includes a longitudinal trend view that shows how each system is aging over time and identifies where intervention may have the greatest impact.
Generation Lab said the system is designed to detect accelerated aging in specific organs before clinical symptoms appear.
The platform also supports per-organ tracking of treatment efficacy for NAD+, peptides, stem cells, therapeutic plasma exchange, hormones, and lifestyle protocols.
Generation Lab said SystemAge 2.1 is built on its proprietary Biological Noise measurement, which measures the standard deviation of DNA methylation values across age-dysregulated cytosines.
The company said this approach differs from linear methylation clocks and is designed to detect fluctuations in methylation patterns as people age or develop disease.
Generation Lab said the approach was published in Aging: The Journal of Clinical and Experimental Research on Aging and validated against healthy and disease cohorts.
SystemAge is currently deployed in more than 750 clinics across 18 countries, including Boulder Longevity Institute, Eterna Health, BioReset Medical, and Extension Health.
The company said the platform has documented an average 5.5-year biological age reduction following stem cell protocols and 10.4 years of immune system reversal following therapeutic plasma exchange.
SystemAge 2.1 is available immediately to existing Generation Lab partner clinics and new clinical partners through the company’s onboarding program.
KEY QUOTE:
“SystemAge is the fastest growing anti-aging diagnostic in the world, with 750+ clinics in 18 countries and growing. With 2.1, we’re giving clinicians the only test that reflects the science we’ve spent decades proving: that aging is sex-specific, organ-specific, and personal. That makes the measurement more useful and the insights more powerful, whether the goal is slowing aging or catching disease before a symptom shows.”
Alina Su, CEO and Co-Founder of Generation Lab
